Association of Endocrine Therapy and Dementia in Women with Breast Cancer

Mikayla R Thompson,1 Jiangong Niu,2 Xiudong Lei,2 Malgorzata Nowakowska,3 Mackenzie R Wehner,2,4 Sharon H Giordano,2,5 Kevin T Nead6,7 1Department of Epidemiology and Environmental Health, University at Buffalo School of Public Health and Health Professions, Buffalo, NY, USA; 2Department of Health S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thompson MR, Niu J, Lei X, Nowakowska M, Wehner MR, Giordano SH, Nead KT
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	breast cancer endocrine therapy dementia aromatase inhibitors selective estrogen receptor modulators Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1a85be8744c9436ca686b91b711473d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a85be8744c9436ca686b91b711473d0
record_format	dspace
spelling	oai:doaj.org-article:1a85be8744c9436ca686b91b711473d02021-12-02T18:13:26ZAssociation of Endocrine Therapy and Dementia in Women with Breast Cancer1179-1314https://doaj.org/article/1a85be8744c9436ca686b91b711473d02021-04-01T00:00:00Zhttps://www.dovepress.com/association-of-endocrine-therapy-and-dementia-in-women-with-breast-can-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Mikayla R Thompson,1 Jiangong Niu,2 Xiudong Lei,2 Malgorzata Nowakowska,3 Mackenzie R Wehner,2,4 Sharon H Giordano,2,5 Kevin T Nead6,7 1Department of Epidemiology and Environmental Health, University at Buffalo School of Public Health and Health Professions, Buffalo, NY, USA; 2Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Medicine, Baylor College of Medicine, Houston, TX, USA; 4Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 6Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 7Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Kevin T Nead Tel +1 713 563-5155Email ktnead@mdanderson.orgPurpose: Prior studies have reported differing results regarding the association between endocrine therapy (ET) in the treatment of breast cancer and dementia risk. However, existing findings may be limited by common sources of bias and confounding. Here we investigate the association of ET utilized in the definitive setting to treat non-metastatic breast cancer with dementia risk accounting for multiple potential sources of bias and confounding.Patients and Methods: We conducted a retrospective study in SEER-Medicare of women aged ≥ 66 years with non-metastatic breast cancer. We examined the risk of all-cause dementia among ET users versus non-ET users using multivariable regression models, accounting for the competing risk of death, and using a start of the follow-up period as 12-months following breast cancer diagnosis for both groups to avoid immortal time bias.Results: Among 25,777 individuals there were 2,869 incident dementia cases. We found a statistically significantly decreased risk of any dementia among ET users in unadjusted and adjusted models that completely attenuated when accounting for the competing risk of death (hazard ratio, 0.98; 95% confidence interval, 0.90– 1.07).Conclusion: When accounting for common sources of bias and confounding we did not find evidence to support an association between ET in the definitive treatment of non-metastatic breast cancer and dementia risk. These results suggest that ET may not be associated with dementia risk.Keywords: breast cancer, endocrine therapy, dementia, aromatase inhibitors, selective estrogen receptor modulatorsThompson MRNiu JLei XNowakowska MWehner MRGiordano SHNead KTDove Medical Pressarticlebreast cancerendocrine therapydementiaaromatase inhibitorsselective estrogen receptor modulatorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 219-224 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer endocrine therapy dementia aromatase inhibitors selective estrogen receptor modulators Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer endocrine therapy dementia aromatase inhibitors selective estrogen receptor modulators Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Thompson MR Niu J Lei X Nowakowska M Wehner MR Giordano SH Nead KT Association of Endocrine Therapy and Dementia in Women with Breast Cancer
description	Mikayla R Thompson,1 Jiangong Niu,2 Xiudong Lei,2 Malgorzata Nowakowska,3 Mackenzie R Wehner,2,4 Sharon H Giordano,2,5 Kevin T Nead6,7 1Department of Epidemiology and Environmental Health, University at Buffalo School of Public Health and Health Professions, Buffalo, NY, USA; 2Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Medicine, Baylor College of Medicine, Houston, TX, USA; 4Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 6Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 7Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Kevin T Nead Tel +1 713 563-5155Email ktnead@mdanderson.orgPurpose: Prior studies have reported differing results regarding the association between endocrine therapy (ET) in the treatment of breast cancer and dementia risk. However, existing findings may be limited by common sources of bias and confounding. Here we investigate the association of ET utilized in the definitive setting to treat non-metastatic breast cancer with dementia risk accounting for multiple potential sources of bias and confounding.Patients and Methods: We conducted a retrospective study in SEER-Medicare of women aged ≥ 66 years with non-metastatic breast cancer. We examined the risk of all-cause dementia among ET users versus non-ET users using multivariable regression models, accounting for the competing risk of death, and using a start of the follow-up period as 12-months following breast cancer diagnosis for both groups to avoid immortal time bias.Results: Among 25,777 individuals there were 2,869 incident dementia cases. We found a statistically significantly decreased risk of any dementia among ET users in unadjusted and adjusted models that completely attenuated when accounting for the competing risk of death (hazard ratio, 0.98; 95% confidence interval, 0.90– 1.07).Conclusion: When accounting for common sources of bias and confounding we did not find evidence to support an association between ET in the definitive treatment of non-metastatic breast cancer and dementia risk. These results suggest that ET may not be associated with dementia risk.Keywords: breast cancer, endocrine therapy, dementia, aromatase inhibitors, selective estrogen receptor modulators
format	article
author	Thompson MR Niu J Lei X Nowakowska M Wehner MR Giordano SH Nead KT
author_facet	Thompson MR Niu J Lei X Nowakowska M Wehner MR Giordano SH Nead KT
author_sort	Thompson MR
title	Association of Endocrine Therapy and Dementia in Women with Breast Cancer
title_short	Association of Endocrine Therapy and Dementia in Women with Breast Cancer
title_full	Association of Endocrine Therapy and Dementia in Women with Breast Cancer
title_fullStr	Association of Endocrine Therapy and Dementia in Women with Breast Cancer
title_full_unstemmed	Association of Endocrine Therapy and Dementia in Women with Breast Cancer
title_sort	association of endocrine therapy and dementia in women with breast cancer
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/1a85be8744c9436ca686b91b711473d0
work_keys_str_mv	AT thompsonmr associationofendocrinetherapyanddementiainwomenwithbreastcancer AT niuj associationofendocrinetherapyanddementiainwomenwithbreastcancer AT leix associationofendocrinetherapyanddementiainwomenwithbreastcancer AT nowakowskam associationofendocrinetherapyanddementiainwomenwithbreastcancer AT wehnermr associationofendocrinetherapyanddementiainwomenwithbreastcancer AT giordanosh associationofendocrinetherapyanddementiainwomenwithbreastcancer AT neadkt associationofendocrinetherapyanddementiainwomenwithbreastcancer
_version_	1718378437164400640

Association of Endocrine Therapy and Dementia in Women with Breast Cancer

Ejemplares similares